Business Description
Regulus Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US75915K1016
Description
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 9.95 | |||||
| Equity-to-Asset | 0.69 | |||||
| Debt-to-Equity | 0.11 | |||||
| Debt-to-EBITDA | -0.08 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 26.3 | |||||
| 3-Year EPS without NRI Growth Rate | 29.5 | |||||
| 3-Year FCF Growth Rate | 26.2 | |||||
| 3-Year Book Growth Rate | -35.3 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 60.94 | |||||
| 9-Day RSI | 60.55 | |||||
| 14-Day RSI | 61.41 | |||||
| 6-1 Month Momentum % | 126.09 | |||||
| 12-1 Month Momentum % | 202.33 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.31 | |||||
| Quick Ratio | 3.31 | |||||
| Cash Ratio | 2.79 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -44.2 | |||||
| Shareholder Yield % | -6.82 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -104.78 | |||||
| ROA % | -76.67 | |||||
| ROIC % | -321.87 | |||||
| ROC (Joel Greenblatt) % | -1188.5 | |||||
| ROCE % | -97.84 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 2.67 | |||||
| Price-to-Tangible-Book | 2.67 | |||||
| EV-to-EBIT | -5.5 | |||||
| EV-to-EBITDA | -5.54 | |||||
| EV-to-FCF | -5.91 | |||||
| Price-to-Net-Current-Asset-Value | 3.06 | |||||
| Price-to-Net-Cash | 3.97 | |||||
| Earnings Yield (Greenblatt) % | -18.18 | |||||
| FCF Yield % | -14.94 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Regulus Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -1.467 | ||
| Beta | 0.71 | ||
| Volatility % | 107.29 | ||
| 14-Day RSI | 61.41 | ||
| 14-Day ATR (€) | 0.138925 | ||
| 20-Day SMA (€) | 2.3965 | ||
| 12-1 Month Momentum % | 202.33 | ||
| 52-Week Range (€) | 1.01 - 2.78 | ||
| Shares Outstanding (Mil) | 65.47 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Regulus Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Regulus Therapeutics Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Regulus Therapeutics Inc Frequently Asked Questions
What is Regulus Therapeutics Inc(STU:7RG0)'s stock price today?
The current price of STU:7RG0 is €2.56. The 52 week high of STU:7RG0 is €2.78 and 52 week low is €1.01.
When is next earnings date of Regulus Therapeutics Inc(STU:7RG0)?
The next earnings date of Regulus Therapeutics Inc(STU:7RG0) is 2024-05-31 Est..
Does Regulus Therapeutics Inc(STU:7RG0) pay dividends? If so, how much?
Regulus Therapeutics Inc(STU:7RG0) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers